Filters
Both acute O2 supplementation and nasal high-flow O2 therapy (NHFO2) result in improvements in exertional dyspnoea and exercise tolerance at “iso-O2 saturation” in severely hypoxemic patients with fibrotic interstitial lung disease (f-ILD), driven primarily by a similar decline in ventilatory requirements, reports a study.
Decreasing exercise tolerance over 3 years is linked to accelerated lung function decline and air trapping progression in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), according to a study.
Short- and long-term exposure to ambient air pollution may worsen COVID-19 outcomes, including acute respiratory distress syndrome (ARDS) and mortality, suggests a study.
Upadacitinib demonstrates its noninferiority to tofacitinib in improving lung transplantation-free survival (LTFS) at 6 months among patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease (MDA5+DM-ILD), reports a study.
Statin use may reduce the risk of cancer at several sites, including the liver, lung, colon, and rectum, especially for individuals with diabetes, as shown in a retrospective study.
Men who are exposed to air pollution may experience changes in genes that are relevant to sperm development, potentially affecting fertility, pregnancy outcomes, and even offspring health, suggests a recent study.
For a carefully selected group of patients with medically refractory, lung-limited, stage IV non-small cell lung cancer (NSCLC), bilateral lung transplant appears beneficial, being associated with favourable early survival outcomes, as shown in a study.
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with obstructive sleep apnoea (OSA) may reduce the incidence of cerebrovascular events, minimize healthcare use, and lower all-cause mortality, according to a retrospective study.
Daily supplementation with multivitamins offers no significant protection against the incidence of COVID-19 in older adults when compared with placebo, as shown in the COSMOS randomized trial.
The use of leukotriene receptor antagonists (LTRAs), especially when combined with H1 antihistamines (H1AHs), can lower the risk of lung cancer in patients with asthma or allergic rhinitis, suggests a study.
